Direct factor Xa inhibitors are anticoagulants, used to both treat and prevent blood clots in veins, and prevent stroke and embolism in people with atrial fibrillation. From Wikipedia
The move follows a restructuring that refocuses spending on deals to strengthen CSL’s bleeding-disorder portfolio.
